Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Ongoing Phase II Study Could Support Accelerated Approval
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
